Randomized trial · people

Tesamorelin: visceral fat down 18% over 52 weeks in HIV patients

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, tesamorelin's drop in visceral fat and triglycerides held for a year of use but did not last once it was stopped.

Kind
Randomized trial
Studied in
People
Published
2008
Journal
AIDS

What they tested

The team tested whether tesamorelin stays safe and keeps its effects on deep belly fat and blood fats when HIV patients use it for a full year, and what happens when they stop.

How the study was done

A randomized, placebo-controlled trial in HIV patients on antiretroviral therapy (HIV medicines) with fat building up around the middle. 273 got tesamorelin 2 mg and 137 got placebo (a dummy shot) under the skin daily for 26 weeks. Then the tesamorelin group was re-randomized to keep going (154) or switch to placebo (50), and the placebo group switched to tesamorelin (111) for another 26 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In people on tesamorelin for the full 52 weeks, visceral adipose tissue (VAT, the deep fat around the organs) stayed 18% lower than at the start (P < 0.001), and triglycerides (a blood fat) stayed 51 mg/dl lower (P < 0.001). Total cholesterol also stayed lower, while HDL cholesterol dropped slightly. Side effects and serious side effects in the second 26 weeks were about as common as in the first, and blood sugar measures did not change in a clinically meaningful way. In people switched from tesamorelin to placebo, the visceral fat came back.

What it doesn’t show

The trial only included HIV patients on antiretroviral therapy with fat buildup around the middle, so it does not show effects in other groups. The extension lasted 26 weeks, and the group switched to placebo was small, at 50 people.

The paper

Falutz et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008.

The compound

More studies on Tesamorelin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo